Patent Cliff By 2016 medicines that generate sales of $133 billion for their manufacturers in the U.S. alone will be exposed to generics, including drugs worth $33.2 billion in 2011 that will lose patent protection in 2012, more than double this year’s figure, according to EvaluatePharma Ltd. Patent Expiry Risk Over Next 3 Years 2010 % of portfolio at sales risk within Company ($ in billions) 3 years Pfizer $53.6 68% Lilly $20.8 66% BMS $15.6 58% J&J $24.3 52% AZ $31.7 50% Amgen $14.6 50% Merck $41.1 43% Sanofi-Aventis $39.9 40% Novartis $45.0 40% GSK $39.6 33% Abbott $19.4 25% Roche $36.2 19% HBA Woman of the Year The Healthcare Businesswomen’s Association (HBA) has named Freda Lewis-Hall, M.D., chief medical officer of Pfizer, 2011 Woman of the Year. In her 30-year career, Dr. Lewis-Hall has held leadership roles in direct patient care, academics, media, government, and pharmaceuticals. In addition, the HBA named Ian Clark, Genentech’s CEO and head of North American commercial operations, as 2011 Honorable Mentor for his dedication to enhancing and accelerating the stature and accomplishments of women in healthcare. Daria Blackwell, healthcare marketing consultant and former managing partner of advertising agency Sudler & Hennessey, has been named the 2011 Star Volunteer. Dr. Lewis-Hall, Mr. Clark, and Ms. Blackwell will be recognized at the 22nd annual “Woman of the Year" (WOTY) Luncheon on Thursday, May 5, 2011. Online Consumers Consumers are three and a half times more likely to go to media and third-party information websites for information about treatments and conditions than to any other source. Only 11% said they would go to a pharma company for health information, according to PricewaterhouseCoopers. M&A Trends In 2010, total M&A transaction value increased by 81% over 2009, reaching $11.62 billion in 2010. Total transaction volume also increased, with a 13% gain over 2009, from 199 in 2009 to 224 in 2010, according to Berkery Noyes. Drug Delivery Market on the Rise The top 10 drug delivery technologies market is expected to grow from $77 billion in 2009 to $156 billion in 2015, with controlled-release technologies accounting for the largest share of $20 billion in revenue in 2010. According to MarketsandMarkets, prominent industry participants include Elan, Biovail, Alkermes, Nektar. inVentiv Goes on Shopping Spree inVentiv Health has acquired Campbell Alliance, a management consulting firm, and signed an agreement to purchase i3 from Ingenix. Paul Meister, executive chairman of inVentiv Health Inc., has assumed the CEO position. inVentiv will realign its organization under three self-standing operating segments: Clinical, Consulting, and Commercial. Going Virtual More life-sciences companies these days are adopting virtual events and environments as part of their training and marketing strategies. Virtual events provide a rich, interactive online space conducive to learning, teaching, training, collaborating, and networking. The Virtual Events for Pharma 2011: How to Create Impact and Maintain Compliance is being brought to you by Unisfair, Cramer, and PharmaVOICE: March 23, 2011, 12:30 ET. » Criterium is celebrating its 20th anniversary of providing global clinical trial and support services to sponsors. “Criterium offers turnkey services, with global locations, transparent processes, and the ability to adapt to the conditions of each clinical study based on the management of real-time information available each day," says John Hudak, founder and president, about his company’s history and its future. » The Pharmaceutical Marketing Research Group (PMRG) marks its 50th anniversary with a year of events and initiatives. To commemorate the milestone in a style suited to the digital era, PMRG has initiated “50 Years in 50 Weeks," a community-generated online look at its legacy of growth, evolution, and leadership. The 1,000+-member organization also has an exciting agenda for its upcoming annual conference March 27-29 in Phoenix, including discussion around the implications of the results of PMRG’s first state-of-the-industry (SOI) survey, an analysis of where the industry stands today, and where it’s poised to go in the future. “While the economy appears to be getting stronger, we are still seeing record numbers of patients enrolling in our prescription savings programs and they are staying in the programs longer," says Rich Fante, President, AstraZeneca U.S. and Regional VP, North America AstraZeneca Provides Free Medication In 2010 AstraZeneca provided $947 million in savings to the more than 545,000 patients in the United States who participated in its AZ&Me prescription savings programs. Through these programs that provide medicines at no cost to eligible participants, AstraZeneca saved patients a total of $2.3 billion on 10.6 million prescriptions since the economic downturn took hold in 2008. Participation in the AZ&Me prescription savings programs has steadily increased over the last three years. In 2010, patients filled 4.1 million prescriptions through the programs, a 7% increase over 2009 and an increase of 34% since 2008. “The shift to a wellness-based and consumer-driven healthcare management and delivery model is one of the most important developments in modern history. " Ron Helm / Pacific Biomarkers Podcasts Best Practices for Your CRO Partnerships Thought Leader: Colin Terry, Aptuit Building a Communications Bridge: A Best Practice for Conducting Clinical Trials in India Thought Leaders: Dr. Edward J. Brennan Jr. and Dr. James A. Bannon, IndiPharm Why ISMPP? Leadership, Value, and Best Practices for Medical Publication Professionals Thought Leaders: Julia Ralston, MedErgy HealthGroup and President ISMPP; and Kimberly Goldin, ISMPP Whitepapers Maximizing the Success of Your CRO Partnerships Sponsored by: Aptuit Increasing Planning Efficiency in Clinical Development Sponsored by: ClearTrial Patient-Centered Wellness: Promoting Savings, Accountability and Health Sponsored by: Cognizant No More Product Losers! Strategic Lessons Learned Sponsored by: Snowfish
